Products

Accelerating precision medicine
in autoimmune diseases

The ScipherIx platform identifies subsets of patient populations within a certain disease, clearly showing that patients cannot be treated uniformly. We develop ScipherDx tests to identify the groups of patients who will not respond to certain drugs so they can be prescribed alternative therapies. ScipherRx finds new targets to help treat specific groups of patients who do not respond to drugs currently on the market 

PrismRA

PrismRA identifies rheumatoid arthritis patients who will not respond to anti-TNFs

PrismUC

PrismUC predicts non-response to anti-TNFs for patients with ulcerative colitis

Both tests have been shown to identify at least half of patients who will not respond to anti-TNFs with at least 90% accuracy – performance requirements set by rheumatologists and gastroenterologists.

PrismRA

Retrospective Observational Trial
Completed
Prospective Observational Trial
In Progress
Prospective Intervention Trial
Planned

PrismUC

Retrospective Observational Trial
Completed
Prospective Observational Trial
In Progress
Prospective Intervention Trial
Planned

Partner with us

We are looking to partner with a pharmaceutical company to advance our targets to the next successful treatment option in IBD
Contact Us

Join a trial

We are recruiting US-based sites and patients to participate in our prospective trials for our diagnostic tests
Learn More